SUNNYVALE, Calif., July 18, 2019 PRNewswire/ -- The Swiss
Medical Network, one of Switzerland's two largest private hospital
groups, has signed a multi-system, multi-clinic agreement to
purchase Accuray Incorporated's radiation therapy delivery systems
as well as RaySearch's treatment planning system (TPS) and oncology
information system (OIS). This is the first multi-system agreement
by a hospital for the purchase of both the Accuray and RaySearch
products. The purchase includes the Accuray
Radixact® and CyberKnife® M6™ Systems,
as well as the RaySearch RayStation® TPS and
RayCare® OIS. Together, these complementary systems will
help enable the Swiss Medical Network team to provide optimal
treatments for patients who may benefit from highly
precise radiation therapy. The first patient treatments using the
combination of the Radixact System and RayStation by the Swiss
Medical Network are anticipated to take place in
2020.
The Swiss Medical Network, (a fully-owned subsidiary of
AEVIS VICTORIA SA), Accuray and
RaySearch will also collaborate on a new training facility, as part
of their continuing commitment to improving cancer care and
patients' quality of life. Healthcare professionals from around the
world will have the opportunity to learn from peers and receive
education on the Radixact and CyberKnife M6 Systems, as well as the
RayStation TPS and RayCare OIS. The state-of-the-art training
facility, unique in Europe, will
enable participating companies to further develop the late stages
of their research programs through direct contact with doctors and
patients of the Clinique de Genolier, the flagship hospital of the
Swiss Medical Network, located in Genolier, Switzerland. The training facility will be
built adjacent to the Clinique de Genolier, on the Swiss
Medical Network Technopark campus.
"At the Swiss Medical Network, our top priority has always
been the well-being of our patients. We foster a multi-disciplinary
approach to treatment led by experts in their field, such as Prof.
Oscar Matzinger, medical director of
radiation oncology for the network, to ensure that cancer patients
have access to the highest quality personalized care during all
stages of their treatment," said Antoine
Hubert, founder of the Swiss Medical Network and delegate of
the board of directors of AEVIS VICTORIA SA. "Our partnership
with Accuray and RaySearch reflects the next step in the evolution
of our radiation therapy offerings as we seek to pioneer and
develop together new ways for optimizing cancer treatment and
improving patients' quality of life. The two organizations have a
history of innovative advancements in radiation oncology, including
many market 'firsts,' which gives me confidence they will help our
team to accomplish our goals long-term."
The Radixact and CyberKnife M6 Systems are next-generation
radiation therapy devices that have been proven to deliver highly
effective treatments for a broad range of tumors almost anywhere in
the body. The systems include advanced functionality that
make it easier and more efficient to administer extremely precise
radiation treatments, providing the clinical team with options for
managing the full spectrum of cancer cases, from routine
to complex and initial treatment to retreatment.
"The Swiss Medical Network is a prestigious organization
and we are proud to work with their team to bring our radiation
therapy systems to more patients in Switzerland. The agreement, involving the
purchase of Accuray delivery devices and RaySearch software,
demonstrates our ability to serve the mainstream market with our
latest generation Radixact and CyberKnife platforms," said
Joshua H. Levine, president and
chief executive officer of Accuray Incorporated. "Accuray is
dedicated to providing customers with the product and service
support they need to meet their clinical and operational
objectives. I believe that our partnership with RaySearch offers a
powerful solution with the potential to truly help their clinical
staff make a meaningful, positive difference in patient
care."
RayStation* is a flexible, innovative treatment planning
system, chosen by many of the leading cancer centers worldwide. It
combines advanced features such as adaptive therapy planning,
multi-criteria optimization and automation using machine learning
and deep learning, with highly accurate and fast dose calculation
engines for photon, electron, proton and carbon ion therapy.
RayStation also seamlessly integrates with RayCare*, the
next-generation oncology information system. RayCare is designed to
support the complex logistical challenges of modern oncology
hospitals. It efficiently coordinates all activities, offer
advanced features for clinical resource optimization, workflow
automation and adaptive radiation therapy.
"We are delighted to collaborate with the Swiss Medical
Network team and provide them with a complete software solution
from RaySearch. The use of RayStation and RayCare together allows
the hospital to deliver highly advanced treatments to cancer
patients and at the same time improve operational efficiency by
powerful workflow management capabilities," said Johan Löf, chief
executive officer and founder of RaySearch. "We have a strong and
fruitful partnership with Accuray and I am convinced that we,
together with the team at Swiss Medical Network, will be able to
create a state-of-the-art clinic and training
facility."
About Swiss Medical Network:
With 17
hospitals spread through 12 cantons cover the country's three
linguistic regions, Swiss Medical Network is the second-largest
group of private hospitals in Switzerland. It has more than 3000 employees
and works with over 2000 doctors. Its growth strategy is based on
the acquisition of existing establishments and the restructuring of
their operations. Its principal goal is to offer top-flight medical
and hospital care to patients from Switzerland and abroad. Swiss Medical Network
sets itself apart with a range of first-class services, its brand
value, a congenial working environment and an entrepreneurial and
experienced management team.
About Accuray
Accuray
Incorporated (Nasdaq: ARAY) develops, manufactures and sells
radiotherapy systems that are intended to make cancer treatments
shorter, safer, personalized and more effective, ultimately
enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook,
LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in
this press release that are not statements of historical fact are
forward-looking statements and are subject to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements in this press release relate, but are
not limited, to clinical applications and results; patient
experiences and outcomes; expectations regarding the first patient
treatments and the training facility discussed in this press
release; Accuray's ability to serve the mainstream market; and
expectations regarding the use of Accuray systems along with
RaySearch offerings and the partnership between Accuray and
RaySearch. These forward-looking statements involve
risks and uncertainties. If any of these risks or uncertainties
materialize, or if any of the company's assumptions prove
incorrect, actual results could differ materially from the results
expressed or implied by these forward-looking statements. These
risks and uncertainties include, but are not limited to, the
company's ability to achieve widespread market acceptance of its
products; the company's ability to develop new products or improve
existing products to meet customers' needs; the company's limited
long-term clinical data supporting the safety and efficacy of its
products and such other risks identified under the heading "Risk
Factors" in the company's quarterly report on Form 10-Q, filed with
the Securities and Exchange Commission (the "SEC") on May 9, 2019 and as updated periodically with the
company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
About RaySearch
RaySearch is
a medical technology company that develops innovative software
solutions to improve cancer care. The company markets the
RayStation treatment planning system and RayCare*, the
next-generation oncology information system, worldwide. Over 2,600
clinics in more than 65 countries use RaySearch's software to
improve life and outcomes for patients. The company was founded in
2000 and the share has been listed on Nasdaq Stockholm since
2003.
For further information, please contact:
Swiss Medical Network
Media
relations: +41 79 635 04 10 or +41 79 607 99
69
Media@swissmedical.net
Accuray
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Doug
Sherk
Investor Relations, EVC
Group
+1 (415)
652-9100
dsherk@evcgroup.com
RaySearch
Johan Löf, President and
CEO, RaySearch Laboratories AB (publ)
Telephone:
+46 (0)8-510 530
00
johan.lof@raysearchlabs.com
Peter Thysell, CFO,
RaySearch Laboratories AB (publ)
Telephone: +46
(0)70 661 05
59
peter.thysell@raysearchlabs.com
*Subject to regulatory clearance in some
markets.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/swiss-medical-network-advances-cancer-care-in-switzerland-with-multi-system-agreement-for-accuray-radiation-therapy-systems-and-raysearch-oncology-software-systems-300887021.html
SOURCE Accuray Incorporated